FDA Issues Third Complete Response Letter for Mallinckrodt’s Terlipressin

The FDA has issued a third Complete Response Letter (CRL) to Mallinckrodt for the company’s investigational drug terlipressin for the treatment of adults with hepatorenal syndrome (HRS), a life-threatening syndrome involving rapid reduction in kidney function.
Source: Drug Industry Daily